#USA #Brentwood #Currax #CONTRAVE #GoodRx

Expanding Access to Weight Loss Medication

Currax Pharmaceuticals LLC, a prominent name in the biopharmaceutical sector, is taking significant strides to make its flagship obesity treatment, Contrave®, more readily accessible to those in need. The company has rolled out a new cash-pay initiative in collaboration with GoodRx, the leading platform for medication savings in the United States. Through this program, patients can now obtain Contrave for as low as $199 per month, enhancing access to one of the top branded oral medications for weight loss that is not part of the GLP-1 category.

Obesity remains a major health challenge in America, affecting over 40% of adults according to CDC reports. Unfortunately, many individuals encounter barriers such as costs and insurance limitations that hinder their ability to seek effective treatment options. With the launch of this program, patients can fill their prescriptions at more than 70,000 pharmacies nationwide, making it easier for millions of Americans to address their weight-related health concerns.

George Hampton, the CEO of Currax Pharmaceuticals, emphasized the company's commitment to patient access: "At Currax, we truly believe in access for all and putting patients at the center of everything we do. By making our cash price available through GoodRx, we are continuing to reduce barriers and provide an easy path for patients to get the treatment they need to manage their weight and improve their overall health."

This collaboration between Currax and GoodRx is seen as a decisive step towards removing obstacles that prevent individuals from accessing essential medications. Dorothy Gemmell, Chief Commercial Officer at GoodRx, highlighted the crucial nature of this initiative: "Though millions of Americans struggle with obesity, weight management medications can be cost-prohibitive—with or without insurance—causing many people to delay or abandon prescribed treatments. These types of access and affordability challenges are why many pharmaceutical companies partner with GoodRx to reduce friction."

Contrave is a prescription-only oral medication intended for adults who are either obese or overweight with associated medical conditions. It is designed to be used alongside a reduced-calorie diet and increased physical activity for effective chronic weight management. The combination of naltrexone and bupropion offers a dual-action approach that aids in controlling appetite and cravings, making it a beneficial aid for many.

Currax is well-known for its commitment to tackling some of the leading causes of preventable deaths in the United States, which include obesity and smoking. Its product lineup features both branded and generic pharmaceutical options that cater to these challenges. As part of their efforts to innovate and improve patient care, this new accessibility program for Contrave reflects Currax's dedication to its mission.

For those impacted by obesity, the new GoodRx cash-price program is a beacon of hope. It signals a shift towards more inclusive health care solutions that prioritize patient needs. With millions of adults living with obesity now gaining access to affordable treatment options, this initiative is set to have a substantial impact on public health moving forward.

To learn more about the GoodRx Contrave savings card, visit GoodRx. Please note that program benefit maximums and eligibility restrictions may apply.

If you're among those seeking effective solutions for obesity, this initiative by Currax might be the lifeline you need to jumpstart your weight management journey. With support from both companies, patients can look forward to improved health and quality of life through accessible medical care.